Bayer Intellectual Property Gmbh

Novosis Pharma Ag

Novosis Ag

Bayer IP Gmbh

Bayer Schering Pharma Ag

Dirk Schenk

Judith Aronhime

Wolfgang Albrecht

Vinod Kumar Kansal

Michael Dittgen

Marina Ratkaj

Richard Guserle

Julia Hrakovsky

Thomas Langguth

Jens Geier

Stefan Bracht

Petra Huber

Jan-Peter Ingwersen

Hubert Kaffl

Stephan Mletzko

German Gassner

Manfred Suesse

Jochen Schumacher

Ralph Stefan

Ashish Tripathi

Roman Safonov

Ramkaran Prajapati

Jochen Schuhmacher

Claudia Lauer

Siva Muppalla

Brijnath Chaurasia

Naveen Srivastav

Pavan Kumar

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

UV stable transdermal therapeutic plaster with a UV absorbing self-adhesive layer separated from the drug matrix

The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.

Transdermal delivery of hormones with low concentration of penetration enhancers

Transdermal delivery of hormones without the need of penetration enhancers

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

UV stable transdermal therapeutic plaster with a UV absorbing adhesive layer separated from the drug matrix

A permeation cell for the in vitro determination of the permeation of pharmaceutical active ingredients through the skin, having a donor chamber ( ) and an acceptor chamber ( ) that is separable therefrom, a window lying between them for receiving sealingly a skin membrane and sealingly closable filling and emptying openings at both chambers, characterized in that the acceptor chamber ( ) is in the form of a cylindrical vessel that is upright during operation, having a closure ( ) at its upper end and a side window opening ( ) in the region near its base, and the donor chamber ( ) is in the form of a connection piece that joins onto the acceptor chamber radially and can be closed at its outer end, with the exception of its closure ( ) the acceptor chamber ( ) is inserted removably into a housing ( ) that fits closely around it, which housing has, in the region of the window opening ( ) of the acceptor chamber, a corresponding slightly wider opening ( ), and the connection piece forming the donor chamber ( ) is screwed removably onto the housing concentrically with the window opening ( ). As a result, the permeation cell gains stability, it is as easy to manipulate as it is to manufacture, auxiliary means for attaching the skin membrane not being required, and the acceptor chamber has only a small dead volume. By constructing the housing ( ) essentially in block form, several such permeation cells can be used next to one another in a common heating and/or stirring device.

Permeation cell for in vitro determination of skin permeation of pharmaceutical drugs

A permeation cell for the in vitro determination of the permeation of pharmaceutical active ingredients through the skin, having a donor chamber (,) and an acceptor chamber (,) that is separable therefrom, a window lying between them for receiving sealingly a skin membrane wherein the acceptor chamber (,) is in the form of a cylindrical vessel that is upright during operation, having a closure (,) at its upper end and a side window opening (,) in the region near its base, and the donor chamber (,) is in the form of a connection piece that joins onto the acceptor chamber radially and can be closed at its outer end. The acceptor chamber (,) is inserted removably into a housing (,), which housing has, in the region of the window opening (,) of the acceptor chamber, a corresponding slightly wider opening (,), and the connection piece forming the donor chamber (,) is screwed removably onto the housing concentrically with the window opening (,).

Permeation cell for invitro determination of skin permeation of pharmaceutical drugs

Growing community of inventors

Dietramszell, Germany

Dirk Schenk